- Results from a Phase 1/2a dose-escalation and expansion study, CA017-003, evaluating the combination of Bristol-Myers Squibb's (BMY -1.3%) Opdivo (nivolumab) and IDO1 inhibitor BMS-986205 in advanced cancers showed a treatment effect. The data will be presented tomorrow, November 11, at the SITC Annual Meeting in National Harbor, MD.
- In the bladder cancer cohort (heavily pretreated), the objective response rate (ORR) was 32% (n=8/25) and the disease control rate (DCR) was 44% (n=11/25).
- In the cervical cancer cohort, ORR was 14% (n=3/22) and DCR was 64% (n=14/22).
- In patients with PD-L1 expression levels at least 1%, ORR rates in bladder and cervical cancer were 46% (n=6/13) and 25% (n=3/12), respectively.
- In patients with PD-L1 expression below 1%, ORR in bladder cancer was 22% (n=2/9). No response was observed in cervical cancer patients (n=0/7).
- IDO1 is an enzyme that breaks down an amino acid called tryptophan which fuels cancer-killing T cells. Tumors that overexpress IDO1 resist immune response because T cells lack the fuel to respond adequately.
- Now read: GlaxoSmithKline Q3 2017: Bear Signals
Original article